Loading...
XJPX
4552
Market cap563mUSD
Dec 05, Last price  
717.00JPY
1D
1.56%
1Q
10.99%
Jan 2017
0.60%
Name

JCR Pharmaceuticals Co Ltd

Chart & Performance

D1W1MN
XJPX:4552 chart
P/E
—
P/S
2.64
EPS
—
Div Yield, %
2.79%
Shrs. gr., 5y
-0.04%
Rev. gr., 5y
5.94%
Revenues
33.07b
-22.86%
7,648,819,0008,544,735,00011,871,886,00012,082,718,00014,387,400,00014,457,846,00012,845,064,00014,099,910,00015,705,912,00016,855,654,00017,438,377,00018,085,035,00020,594,000,00023,160,000,00024,781,000,00030,085,000,00051,082,000,00034,343,000,00042,871,000,00033,072,000,000
Net income
-4.76b
L
-31,864,000-1,751,061,000399,972,000539,911,0001,302,874,000926,473,000633,989,000730,715,0001,296,206,0001,682,368,0001,789,474,0001,863,170,0003,070,000,0003,715,000,0002,678,000,0006,892,000,00014,507,000,0003,772,000,0005,507,000,000-4,758,000,000
CFO
-5.49b
L
746,573,0001,129,455,0001,923,514,0001,825,586,0002,357,537,000-18,331,000-421,110,0001,661,364,0004,565,361,000499,052,0002,201,746,0002,651,346,0003,133,000,0003,905,000,0004,927,000,00010,341,000,0009,289,000,000-5,500,000,0009,312,000,000-5,486,000,000
Dividend
Mar 30, 202610 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
URL
https://www.jcrpharm.co.jp/
IPO date
Mar 16, 1995
Employees
879
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT